Introduction {#s1}
============

Proteasome inhibition elicits a response to restore proteasome activity, or a \'bounce-back response,\' where Nrf1 is the responsible transcription factor that upregulates expression of all proteasome subunit genes in a concerted manner in human cells ([@bib9]; [@bib12]). Proteasome inhibitors such as bortezomib and carfilzomib have been in clinical use for treatment of cancers, especially multiple myeloma, but this bounce-back response attenuates the ability of proteasome inhibitors to kill cancer cells ([@bib9]). Therefore, genes regulating Nrf1 activation could be useful drug targets for increasing efficacy of proteasome inhibition in cancer treatment.

When Nrf1 is produced, the bulk of the polypeptide is inserted into the ER lumen and glycosylated, with a short cytosolic N-terminus followed by a single transmembrane domain ([@bib8]; [@bib15]). The luminal region of Nrf1 is continually retrotranslocated to the cytosol by the p97/VCP ATPase complex, accompanied by deglycosylation and ubiquitination. Under normal circumstances, Nrf1 is promptly degraded by the proteasome. In contrast, when proteasome activity is compromised, Nrf1 escapes degradation and is proteolytically cleaved to the active form which enters the nucleus and enhances expression of target genes including proteasome subunits ([@bib8], [@bib9]; [@bib10]; [@bib12]). However, the processing enzyme for Nrf1 remains obscure.

Results and discussion {#s2}
======================

To identify genes important for Nrf1 activation, we performed a genome-wide small interfering RNA (siRNA) screen ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). Our approach used the well-characterized subcellular localization of Nrf1 accumulation in the nucleus in response to proteasome inhibition. HEK293A cells were transfected with pooled siRNA (a pool of 4 unique siRNAs per gene) and then treated with the proteasome inhibitor bortezomib to induce accumulation and nuclear translocation of Nrf1 ([@bib12]). Cells were then fixed and stained with anti-Nrf1 antibody. The ratio of the nuclear to cytoplasmic fluorescent intensities was assessed by high-content microscopy and automated image analysis ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}). p97 siRNA treatment served as a positive control, which abolished Nrf1 translocation following bortezomib treatment while increasing cytoplasmic Nrf1 ([Figure 1A](#fig1){ref-type="fig"}) ([@bib8]). We observed a high degree of assay robustness (Z'-factor \> 0.5, [Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}) in the primary screen. The initial candidate genes with B score \< --3.2 ([Figure 1B](#fig1){ref-type="fig"}) or which were picked up by visual inspection of the raw image data were further tested using four individual siRNAs in two different cell lines (HEK293A and HT1080 cells) ([Figure 1C](#fig1){ref-type="fig"}). The subsequent candidates that had more than two hits in either cell line were finally examined whether the siRNAs mitigated upregulation of *PSMA3*, a proteasome subunit gene. Consequently, we obtained 14 candidate genes that may impair activation of Nrf1 in response to bortezomib treatment ([Figure 1D](#fig1){ref-type="fig"}). These hits included SEL1L, a co-factor of the ubiquitin ligase HRD1, which catalyzes ER-associated degradation (ERAD) of Nrf1 ([@bib1]; [@bib12]; [@bib14]) and FAF2/UBXD8, a p97-recruiting molecule in ERAD ([@bib6]), validating our screening approach ([Figure 1A,B, and D](#fig1){ref-type="fig"}).10.7554/eLife.18357.003Figure 1.A genome-wide siRNA screen for regulators of Nrf1 translocation to the nucleus in response to proteasome inhibition.(**A**) Representative images of Nrf1 localization in control cells (no siRNA) and cells transfected with siRNA targeting p97 or SEL1L in the primary screen. Yellow-boxed regions are magnified and displayed in the right panels. (**B**) B score of all samples in the primary screen. Data are ordered from lowest to highest. Dashed blue line represents a cutoff value for positive hits. Some of the representative final hits are shown as red dots. The list of B scores for all samples in the primary screen are available in the [Figure 1---source data 1](#SD1-data){ref-type="supplementary-material"}. (**C**) Workflow and summary of the genome-wide siRNA screen. (**D**) List of the 14 final hit genes and the score in each assay throughout the screening process.**DOI:** [http://dx.doi.org/10.7554/eLife.18357.003](10.7554/eLife.18357.003)10.7554/eLife.18357.004Figure 1---source data 1.List of B-score in the primary screen.**DOI:** [http://dx.doi.org/10.7554/eLife.18357.004](10.7554/eLife.18357.004)10.7554/eLife.18357.005Figure 1---figure supplement 1.Methods for the genome-wide screen.(**A**) A schematic view of the workflow in the primary screen using HEK293A cells. (**B**) Definition of nucleus and cytoplasm in the screen. Region of interest (ROI) of the nucleus was defined as a circle drawn two pixels inside of the outermost DAPI signal. ROI of the cytoplasm was defined as a three-pixel wide ring around DAPI signal. No gap between the rings and DAPI signals was set in the analysis using HEK293A cells, whereas a one-pixel gap was set in the analysis using HT1080 cells. (**C**) The well score of negative (no siRNA) and positive (si p97) controls. The well score is the fluorescence intensity ratio of ROI of nucleus to cytoplasm as defined in (**B**). The Z' factor was calculated from 12 individual wells on each plate.**DOI:** [http://dx.doi.org/10.7554/eLife.18357.005](10.7554/eLife.18357.005)

Among the final hit genes, we focused on DDI2, because it has a typical retroviral aspartyl protease domain, and therefore is a candidate Nrf1 processing enzyme ([@bib3]). In negative and positive (p97 siRNA) control cells treated with bortezomib, the majority of Nrf1 is localized in the nucleus and the cytoplasm, respectively ([Figure 2A](#fig2){ref-type="fig"}). DDI2 knockdown partially inhibited nuclear translocation of Nrf1, accompanied by an increase in cytoplasmic Nrf1. To determine if there is a defect in Nrf1 processing by DDI2 knockdown, we examined which Nrf1 species were observed in each knockdown. In negative control cells, Nrf1 was hardly detected in the absence of bortezomib, but bortezomib treatment increased the processed, active form of Nrf1 as well as the full-length, cytosolic form that is retrotranslocated into the cytosol by p97 ([Figure 2B](#fig2){ref-type="fig"}) ([@bib8]). In p97 knockdown cells, the luminal ER form of Nrf1 that is N-glycosylated accumulated while the processed form almost disappeared both in the presence and absence of bortezomib. In DDI2 knockdown cells, Nrf1 was not detected in the absence of bortezomib, similar to control cells. However, in the presence of bortezomib, the full-length, cytosolic form of Nrf1 markedly accumulated ([Figure 2B](#fig2){ref-type="fig"}). These results indicate that DDI2 is involved in conversion of full-length, cytosolic Nrf1 to the processed, active form.10.7554/eLife.18357.006Figure 2.DDI2 is involved in Nrf1 processing and translocation to the nucleus.(**A**) Representative images of Nrf1 localization. HEK293A cells were transfected with a non-targeting control (negative control), DDI2, or p97 siRNA and then treated with 50 nM bortezomib for 14 hr before fixation. (**B**) Immunoblotting of whole-cell lysates of cells in (**A**) treated with or without bortezomib. Nrf1 is detected as three different forms; a glycosylated form (G), full-length form (FL), and processed form (P). (**C**) Immunoblotting of Nrf1 after deglycosylation treatment. HEK293A cells were transfected with DDI2 or p97 siRNA, followed by transfection with Nrf1-3×Flag, and then treated with or without 50 nM bortezomib. The cell lysates were treated with or without Endo H. DeG denotes deglycosylated Nrf1.**DOI:** [http://dx.doi.org/10.7554/eLife.18357.006](10.7554/eLife.18357.006)10.7554/eLife.18357.007Figure 2---figure supplement 1.The expression and localization of DDI2 were not affected by bortezomib treatment.(**A**) Relative mRNA expression of *DDI2* in HCT116 cells treated with or without bortezomib (50 nM, 14 hr). The data represent mean + standard error of the mean (SEM) (n = 3, biological replicates). (**B**) Subcellular localization of DDI2. HEK293A cells stably expressing Venus-Sec61β (ER marker) were transfected with Flag-DDI2 and treated with or without bortezomib.**DOI:** [http://dx.doi.org/10.7554/eLife.18357.007](10.7554/eLife.18357.007)

We further examined the N-glycosylation status of Nrf1 using cells transfected with Nrf1 tagged with 3×Flag at the C-terminus. N-glycosylated Nrf1 accumulated in p97 knockdown cells was sensitive to endoglycosidase H (Endo H) treatment and the deglycosylated form migrated faster in SDS-PAGE, consistent with a previous report ([Figure 2C](#fig2){ref-type="fig"}) ([@bib8]). In contrast, the full-length form of Nrf1 that is significantly accumulated in DDI2 knockdown cells was not sensitive to Endo H treatment ([Figure 2C](#fig2){ref-type="fig"}). Note that bortezomib treatment alone causes some accumulation of Endo H-sensitive N-glycosylated Nrf1 and that the deglycosylated species was detected at almost the same molecular weight as the processed, active form of Nrf1 observed in cells treated with bortezomib alone, similar to previously reported observations ([Figure 2C](#fig2){ref-type="fig"}) ([@bib8]). These results demonstrate that the form of Nrf1 accumulated in DDI2-depleted cells is not N-glycosylated, further supporting the role of DDI2 in the processing of Nrf1 rather than in deglycosylation or retrotranslocation.

The X-ray crystal structure analysis of the retroviral aspartyl protease (RVP) domain of budding yeast Ddi1p has revealed that it is a dimer with a similar fold to that of the human immunodeficiency virus type 1 (HIV-1) protease, with identical geometry of the double D\[S/T\]GA motif of the active site ([@bib11]). The HIV-1 protease typically cleaves substrates between two hydrophobic residues ([@bib2]). Nrf1 has been shown to be cleaved between Trp103 and Leu104 to become active ([@bib8]), which conforms with the cleavage motif by retroviral aspartyl proteases. Accordingly, we asked whether the protease activity of DDI2 is required for Nrf1 processing. DDI2 has a ubiquitin-like domain (UBL) at the N-terminus and a RVP domain near the C-terminus ([Figure 3A](#fig3){ref-type="fig"}). Bortezomib treatment increased the processed form of Nrf1 ([Figure 3B](#fig3){ref-type="fig"}). Knockdown of DDI2 reduced the processed form and increased full-length Nrf1 ([Figure 3B](#fig3){ref-type="fig"}). This effect was rescued by introducing siRNA-resistant wild-type DDI2 but not a protease-dead DDI2 in which the active site aspartic acid 252 was replaced with asparagine (D252N). We also found that a DDI2 mutant lacking the UBL domain only partially restored the effect of DDI2 knockdown ([Figure 3B](#fig3){ref-type="fig"}). These results suggest that the protease activity of DDI2 is required for cleavage of Nrf1 and that the UBL domain plays some role in the cleavage.10.7554/eLife.18357.008Figure 3.The protease activity of DDI2 is necessary for Nrf1 processing and its transcriptional activity.(**A**) Schematic diagram of wild-type (WT) and each mutant of DDI2. Ubiquitin-like (UBL) domain and retroviral protease-like (RVP) domain are represented as filled rectangles. The putative aspartyl protease active site amino acid sequence is shown. (**B**) HEK293A cells were transfected with DDI2 siRNA and after 24 hr were transfected with a plasmid encoding WT or mutant DDI2 shown in (**A**), followed by 50 nM bortezomib treatment for 14 hr before harvest. The signal intensity ratio of Nrf1 full-length form (FL) to the processed form (P) was calculated, where the ratio for bortezomib treatment alone was set as 1. (**C**) Immunoblotting of whole cell lysates of DDI2 WT knock-in (KI), DDI2 knockout (KO), and DDI2 D252N KI HCT116 cells. The cells transfected with Nrf1-3×Flag were treated with or without 50 nM borteaomib. (**D**) Relative mRNA expression of the proteasome genes *PSMA3* and *PSMB5* in WT, DDI2 KO, DDI2 WT KI, and DDI2 D252N KI HCT116 cells. mRNA levels of target genes were normalized by *GUSB* mRNA levels. The data represent mean + standard error of the mean (SEM) (n = 3, biological replicates). Statistical comparison was made by Tukey's test (\*p\<0.05). (**E**) Proteasome peptidase activity of cell lysates of the indicated cell lines. The data represent mean + SEM (n = 3, biological replicates). Statistical comparison was made by Tukey's test (\*\*p\<0.01).**DOI:** [http://dx.doi.org/10.7554/eLife.18357.008](10.7554/eLife.18357.008)10.7554/eLife.18357.009Figure 3---figure supplement 1.Genome editing of *DDI2* locus by CRISPR-Cas9 system.(**A**) Schematic diagram of *DDI2* wild-type (WT), knockout (KO), and knock-in (KI) alleles. Red arrowhead indicates sgRNA targeting site, and blue arrows indicate PCR primers for confirmation of homologous recombination. puro^R^ indicates a puromycin resistant cassette. (**B**) Confirmation of successful genome editing at the *DDI2* locus. The genome DNA of each cell line was extracted and amplified by PCR using primer pairs shown in (**A**).**DOI:** [http://dx.doi.org/10.7554/eLife.18357.009](10.7554/eLife.18357.009)

To confirm the necessity of the protease activity of DDI2, we generated DDI2 knockout (KO) and protease-dead DDI2 (D252N) knock-in (KI) cells as well as wild-type DDI2 knock-in cells ([Figure 3](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1A,B](#fig3s1){ref-type="fig"}). In DDI2 knockout cells and DDI2 D252N knock-in cells, the full-length form of Nrf1 was accumulated upon bortezomib treatment, whereas the processed form was accumulated in wild-type DDI2 knock-in cells ([Figure 3C](#fig3){ref-type="fig"}). These results further support the requirement of DDI2 protease activity for Nrf1 activation.

We then examined whether a lack of the catalytic activity of DDI2 abolishes the \'bounce-back\' response after proteasome inhibition. In parental HCT116 cells, bortezomib treatment caused an increase in mRNA levels of the proteasome subunit genes *PSMA3* and *PSMB5* ([Figure 3D](#fig3){ref-type="fig"}). Knockout of DDI2 strongly suppressed this response, further supporting the importance of DDI2 in Nrf1 activation ([Figure 3D](#fig3){ref-type="fig"}). Interestingly, the basal expression of proteasome subunits was also decreased in DDI2-deficient cells. In wild-type DDI2 knock-in cells, mRNA levels of the proteasome subunits were upregulated in response to bortezomib, similar to the parental cells. In contrast, DDI2 D252N knock-in cells did not undergo such a response, similar to DDI2 knockout cells ([Figure 3D](#fig3){ref-type="fig"}). These results suggest that the processing of Nrf1 by the aspartyl protease activity of DDI2 is required for upregulation of proteasome gene expression mediated by Nrf1 in response to proteasome inhibition.

Nrf1 has also been found to regulate basal expression of proteasome subunits, the extent of which varies between cell types ([@bib4], [@bib5]). We observed that knockout and D252N DDI2 knock-in cells had significantly lower proteasome activity compared to wild-type DDI2 knock-in cells, suggesting that DDI2 is also involved in basal expression of proteasomes through its catalytic activity ([Figure 3E](#fig3){ref-type="fig"}).

In conclusion, we identified DDI2 as a protease that is required for Nrf1 processing and the bounce-back response induced by proteasome inhibition. However, there remain several questions to be answered. How can the involvement of DDI2 be reconciled with a previous report that demonstrated a defect in Nrf1 processing by strong inhibition of the proteasome, leading to the conclusion that the proteasome is the processing enzyme for Nrf1 ([@bib10])? In terms of substrate specificity, the cleavage site of Nrf1 (P1: W, P1': L) does not seem to be a sequence preferred by the proteasome ([@bib13]); rather it conforms to a cleavage motif of RVP ([@bib2]). It could be that the proteasome activity is required for function of DDI2 or some other factors that is involved in Nrf1 processing. Related to this, the mechanism by which DDI2 acts as a Nrf1 processing protease remains unclear. DDI2 is not induced by bortezomib at either protein or mRNA level ([Figure 2B](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}). Furthermore, the subcellular localization of DDI2 seems to be unaffected by bortezomib treatment ([Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}). Since DDI2 is suggested to be active even when the proteasome activity is not compromised ([Figure 3D and E](#fig3){ref-type="fig"}), a specific activation mechanism under proteasome impairment may not exist. An intriguing finding is that the UBL domain of DDI2 plays some role in Nrf1 processing ([Figure 3B](#fig3){ref-type="fig"}). It has been shown that the UBL domain of Ddi1p is an atypical UBL that binds ubiquitin ([@bib7]). Binding of DDI2 with ubiquitinated proteins, possibly Nrf1 itself, would be promoted by proteasome inhibition and may facilitate Nrf1 processing by DDI2. Lastly, whether DDI2 directly cleaves Nrf1 remains unknown. We have tested a recombinant fragment of Nrf1 encompassing the processing site as a substrate for recombinant DDI2, but failed to detect its cleavage. Other factors might be required for in vitro reconstitution of Nrf1 processing by DDI2, such as substrate unfolding, co-activators of DDI2, and a set of specific experimental conditions. Understanding the mechanism by which DDI2 cleaves Nrf1 and establishing an in vitro assay for the enzymatic activity of DDI2 should provide useful information for developing a DDI2 inhibitor that would block compensatory proteasome synthesis to improve cancer therapies targeting proteasomes.

Materials and methods {#s3}
=====================

Genome-wide siRNA screening {#s3-1}
---------------------------

In the primary screen, Dharmacon siGENOME SMARTpool siRNA library (GE Dharmacon, Lafayette, CO) was used. To prepare screening plates, the siRNAs in each well were suspended in 1 × siRNA buffer (Thermo Fisher Scientific, Waltham, MA) and 2.5 pmol siRNA (2.5 μL/well) was dispensed into black, clear bottom, 384-well plates (Greiner, Kremsmünster, Austria). For each well, a mixture of 10 μL DMEM and 0.1 μL Lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA) was added. After 40 min incubation, 2000 cells/well of HEK293A cells were seeded. After 48 hr culture, bortezomib was added into each well to a final concentration of 10 nM. Cells were fixed with 4% PFA after 12 hr bortezomib treatment. Cells were then stained with Nrf1 antibody (sc-13031; Santa Cruz Biotechnology, Dallas, TX) and DAPI, and the fluorescent images were acquired and analyzed by CellInsight High Content Screening Platform (Thermo Fisher Scientific). The fluorescence signal ratio of the nucleus to the cytoplasm was used as a raw measured value. The value was fitted in a two-way median polish method to exclude positional effects in the 384-well plate, and then the B score was calculated on a per-plate basis using the following formula.$${B\ score\  = \ (X}_{i}{\  - \ Median)\ /\ MAD}$$$${(X}_{i}{:\ measured\ value,\ MAD:\ median\ of\ absolute\ deviation)}$$

In the secondary screen, four individual siRNAs contained in the library were purchased from Dharmacon and used. HEK293A and HT1080 cells transfected with each siRNA were analyzed by the same method as in the primary screening. In the third screen, HEK293A cells were treated with each hit siRNA and the expression level of the proteasome gene *PSMA3* was measured by quantitative RT-PCR.

DNA constructs {#s3-2}
--------------

Human DDI2 cDNA was synthesized from total RNA extracted from HT1080 cells using the indicated primers. Forward: 5'-ATGCTGCTCACCGTGTACTGTGTGC-3', Reverse: 5'-TCATGGCTTCTGACGCTCTGCATCC-3'. DDI2 UBL deletion mutant was synthesized using 5'-AACTTACCCCGAATAGATTTCAG-3' for a forward primer. siRNA resistant mutations were introduced without changing amino acid sequence using the following primers. Forward: 5'- TAATGTTGTATATTAACTGCAAAGTGAATGGACATCCTG-3', Reverse: 5'- CGACCTGTCCAAAACTTTCCGGAGCCTCTTCCATAGC-3'. Human Nrf1 cDNA was synthesized from total RNA extracted from HEK293A cells using the indicated primers. Forward: 5'-ATGCTTTCTCTGAAGAAATACTTAACG-3', Reverse: 5'-TCACTTTCTCCGGTCCTTTGG-3'. PCR was performed using PrimeSTAR Max DNA polymerase (Takara Bio, Shiga, Japan). Amplified fragments were subcloned into pIRES vector (Clontech Laboratories, Mountain View, CA) and all constructs were confirmed by sequencing.

Cell culture and transfection {#s3-3}
-----------------------------

HEK293A cells were purchased from Thermo Fisher Scientific. HCT116 cells were obtained from RIKEN BRC. The cell lines were tested negative for mycoplasma contamination by DAPI staining. The authors performed no further authentication of the cell lines. HEK293A cells and HCT116 cells were cultured under standard conditions. cDNAs were transfected into cells using PEI-MAX (Mw: 40,000). siRNAs targeting DDI2 or p97 and siGENOME Non-Targeting siRNA \#2 were purchased from GE Dharmacon. siRNA was transfected into cells with Lipofectamine RNAi MAX (Invitrogen). The sequences of siRNAs targeting DDI2 and p97 were as follows: DDI2, 5'-GCCAAGUAGUGAUGCUUUA-3'; p97, 5'-GUAAUCUCUUCGAGGUAUA-3'.

Establishment of DDI2 knockout and knock-in cell lines {#s3-4}
------------------------------------------------------

The cell lines were established using the CRISPR/Cas9 system. Single guide RNAs (sgRNA) were designed using CRISPR direct (<http://crispr.dbcls.jp/>) and cloned into a pX330 vector. The sgRNA sequence for *DDI2* was 5'-ACTCGAGCTCGCACAGCGCG-3'. Targeting constructs for gene knockout were designed to insert a puromycin resistance cassette at the locus of the start codon. Targeting constructs for DDI2 knock-in were designed to insert DDI2 wild type or D252N cDNA in-frame downstream of DDI2 exon 1. A puromycin resistance cassette was also inserted into this region. The sgRNA vector and targeting vector were transfected in HCT116 cells. After 48 hr transfection, cells were cultured in medium supplemented with 4 μg/mL puromycin. After two weeks drug selection, colonies were picked up and successful homologous recombination was confirmed by PCR method. PCR was performed using EmeraldAmp PCR Master Mix (Takara Bio). The following primers were used for confirmation of genome editing. DDI2 Forward: 5'-ATGCTGCTCACCGTGTACTGTGTGC-3', DDI2 intron 1 Reverse: 5'-GCAAGCTGAGTAGGGAAATGAAACCACCAA-3', Puro forward: 5'-GTCACCGAGCTGCAAGAACTCTTCC-3'.

Quantitative RT-PCR {#s3-5}
-------------------

Cells were harvested 12 hr after 20 nM bortezomib treatment. Total RNA of cells was isolated using High Pure RNA isolation kit (Roche, Basel, Switzerland) and were reverse-transcribed using ReverTra Ace qPCR RT kit (Toyobo, Osaka, Japan). Quantitative RT-PCR was performed using THUNDERBIRD Probe qPCR Mix (Toyobo), Universal ProbeLibrary Probe (Roche), and LightCycler 480 (Roche). The sequences of primers used were as follows: *PSMA3*, 5'-GAAGAAGCAGAGAAATATGCTAAGG-3' and 5'-GGCTAAATAGTTACATTGGACTGGAG-3'; *PSMB5*, 5'-CATGGGCACCATGATCTGT-3' and 5'-GAAATCCGGTTCCCTTCACT-3'; *GUSB*, 5'-CGCCCTGCCTATCTGTATTC-3' and 5'-TCCCCACAGGGAGTGTGTAG-3'.

Immunoblotting {#s3-6}
--------------

24 hr after transfection of siRNA, cells were transfected with cDNA and cultured for a further 48 hr. 50 nM bortezomib was added 14 hr prior to cell lysis. Cells were lysed in buffer containing 42 mM Tris-HCl (pH 6.8), 1.72% SDS, 5.6% glycerol, 5% 2-mercaptoethanol, and 0.01% bromophenol blue (SDS sample buffer) for whole-cell lysate. The samples were subjected to SDS-PAGE, transferred to polyvinylidene fluoride membrane, and analyzed by immunoblotting. All images were taken using Fusion SL4 (M&S Instruments). Rabbit polyclonal antibody against DDI2 was raised by immunizing keyhole limpet hemocyanin (KLH) conjugated synthetic DDI2 C-terminal (residues 385--399) peptides. The following antibodies were purchased: Nrf1 (sc-13031; Santa Cruz), p97 (MA3-004; Invitrogen), GAPDH (sc-32233; Santa Cruz), Flag (F1804; Sigma Aldrich, St. Louis, MO).

Immunostaining {#s3-7}
--------------

Cells were fixed in 4% paraformaldehyde 72 hr after transfection of siRNA and 16 hr after 10 nM bortezomib treatments. The cells were incubated with primary antibodies, and then incubated with DAPI (Nacalai Tesque, Kyoto, Japan) and secondary antibodies, either Goat anti-rabbit or anti-mouse IgG secondary antibody Alexa Fluor 488 or Alexa Fluor 647 conjugate (Invitrogen). All images were acquired by TCS SP5 or TCS SP8 (Leica Microsystems, Wetzlar, Germany).

Proteasome activity measurement {#s3-8}
-------------------------------

Cells were lysed in ice-cold buffer containing 25 mM Tris-HCl (pH 7.5), 0.2% Nonidet P-40, 1 mM dithiothreitol, 2 mM ATP, and 5 mM MgCl~2~. The hydrolysis of the fluorogenic peptide, succinyl-Leu-Leu-Val-Tyr-7-amino-4-methylcoumarin (Suc-LLVY-MCA) (Peptide Institute, Osaka, Japan) was measured in 50 mM Tris-HCl (pH 8.0) at 37°C by ARVO MX 1420 (PerkinElmer, Waltham, MA).

Deglycosylation assay {#s3-9}
---------------------

Cells were lysed in ice-cold phosphate buffered saline (PBS) containing 0.5% Triton X-100. After centrifugation (20,000 g, 10 min), the cell lysates were subjected to deglycosylation reactions with Endo H~f~ (New England BioLabs, Ipswich, MA) following the manufacturer's protocol.

Statistical analysis {#s3-10}
--------------------

A biological replicate was considered as each independent experiment. Each different clone of the same genotypes was also considered as a biological replicate in the experiments using mutant cell lines obtained by the CRISPR-Cas9 system. Technical replicates were multiple analyses of the same sample in an experiment. The results are expressed as mean + standard error of the mean (SEM) of three biological replicates (n = 3). Significant differences were considered as probabilities less than 5% (p\<0.05).
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"The aspartyl protease DDI2 activates Nrf1 to compensate for proteasome dysfunction\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by Ivan Dikic as the Senior and Reviewing Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Raymond J Deshaies (Reviewer \#1) and Anne Bertolotti (Reviewer \#2).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

The manuscript by Koizumi et al. identifies DDI2 as a candidate enzyme that mediates the cleavage and activation of the transcription factor Nrf1 (NFE2L1). The manuscript starts with an unbiased genome-wide siRNA screen aimed at identifying genes important for Nrf1 activation. This yielded 14 candidate genes, including DDI2, which is known to have an aspartyl protease domain homologous to that of the HIV protease. Subsequent experiments demonstrated diminished nuclear localization and processing of Nrf1, and diminished induction of proteasome genes, in DDI2-deficient cells treated with proteasome inhibitor. It was also shown that the active site of DDI2 is required to promote processing of Nrf1 and bortezomib-induced expression of proteasome genes. The authors also showed that DDI2 can be targeted by inhibitors of HIV protease and that these inhibitors improve the efficacy of Bortezomib.

The findings presented in this manuscript are technically convincing and targeting the bounce-back response upon proteasome inhibition is indeed of importance at several levels: to improve our knowledge on the regulation of proteasome upregulation and to improve cancer therapies based on proteasome inhibition.

Essential revisions:

1\) Did the authors attempt a protease protection experiment to examine the disposition of Nrf1 in DDI2-depleted cells? Based on the data [Figure 2B](#fig2){ref-type="fig"}, the authors conclude that Nrf1 has been retrotranslocated and deglycosylated in DDI2-depleted cells, but this is not formally proven. It is possible that DDI2 regulates Nrf1 in some other manner that is upstream of the processing step (e.g. retrotranslocation), and the MW shift occurs for some other reason other than deglycosylation. While this may be unlikely, it is certainly possible and should be commented.

2\) Figure 4 is weak, and all reviewers felt that needs to be significantly improved or removed. This is not a point that is strictly necessary for the central finding of the paper that DDI2 is required for processing. The real question is whether it can be improved by additional data (see below) or should be removed from the current manuscript. For example, the effects in panel A are weak and would benefit from a titration to higher concentrations. Panel B is even weaker. Other groups have reported that there is some synthetic effect of combining proteasome inhibitors with HIV protease inhibitors (e.g. the Kraus and Driessen papers cited in the Results and Discussion). So, what is new about this figure? The big question is, what is the underlying mechanism? Is it really due to inhibition of DDI2? A couple of questions related to this experiment immediately come to mind. Are DDI2∆ cells, like NRF1∆ cells, more sensitive to bortezomib? Is the synthetic effect of combining bortezomib and NFV or LPV still observed in DDI2∆ cells? Is it observed in NRF1∆ cells? So we recommend to the authors to decide one of these two options related to Figure 4.

3\) The authors have established DDI2 knock-out cells (DDI2 KO) and DDI2 KO cells in which the WT or protease-dead mutant DDI2 cDNA was knock-in to the DDI2 locus. It would be useful to analyse the processing of Nrf1 in these cell lines upon proteasome inhibition to complement the siRNA knocked down experiments.

4\) The authors should discuss why both forms (FL and P) of Nrf1 are decreasing after co-treatment with bortezomib and lopinavir. Could it be due to cell death or off-target effect of this drug? Is lopinavir treatment alone also decreasing the levels of Nrf1?

10.7554/eLife.18357.011

Author response

*Essential revisions:*

*1) Did the authors attempt a protease protection experiment to examine the disposition of Nrf1 in DDI2-depleted cells? Based on the data [Figure 2B](#fig2){ref-type="fig"}, the authors conclude that Nrf1 has been retrotranslocated and deglycosylated in DDI2-depleted cells, but this is not formally proven. It is possible that DDI2 regulates Nrf1 in some other manner that is upstream of the processing step (e.g. retrotranslocation), and the MW shift occurs for some other reason other than deglycosylation. While this may be unlikely, it is certainly possible and should be commented.*

We examined whether the Nrf1 species accumulated in DDI2-depleted cells is deglycosylated using endoglycosidase H (Endo H), which removes N-linked glycosylation. In p97-depleted cells, the accumulated Nrf1 band was sensitive to Endo H treatment, consistent with the previous studies and indicating that the two bands correspond to glycosylated "G" and deglycosylated "DeG" forms of Nrf1. In contrast, the Nrf1 form "FL" accumulated in DDI2-depleted cells is not sensitive to Endo H treatment, indicating that this form is not glycosylated and that the "FL" form is a product after retrotranslocation. Curiously, the migration of "DeG" and "FL" does not correspond to each other. This phenomenon was also observed in a previous report, though the precise reason is yet unknown (Radhakrishnan et al. 2014). These results are newly added as [Figure 2C](#fig2){ref-type="fig"} and described in the third paragraph of the Results and Discussion in the revised manuscript.

We also performed protease protection experiments to examine whether Nrf1 retrotranslocation was inhibited, but we were unable to obtain clear results. However, DDI2-depleted cells show accumulation of deglycosylated Nrf1, in contrast to p97-depleted cells ([Figure 2B and C](#fig2){ref-type="fig"}). As deglycosylation of ER-associated degradation substrates are generally completed in the cytoplasm after retrotranslocation from the ER, this result suggests that Nrf1 is retrotranslocated in DDI2-depleted cells.

*2) Figure 4 is weak, and all reviewers felt that needs to be significantly improved or removed. This is not a point that is strictly necessary for the central finding of the paper that DDI2 is required for processing. The real question is whether it can be improved by additional data (see below) or should be removed from the current manuscript. For example, the effects in panel A are weak and would benefit from a titration to higher concentrations. Panel B is even weaker. Other groups have reported that there is some synthetic effect of combining proteasome inhibitors with HIV protease inhibitors (e.g. the Kraus and Driessen papers cited in the Results and Discussion). So, what is new about this figure? The big question is, what is the underlying mechanism? Is it really due to inhibition of DDI2? A couple of questions related to this experiment immediately come to mind. Are DDI2∆ cells, like NRF1∆ cells, more sensitive to bortezomib? Is the synthetic effect of combining bortezomib and NFV or LPV still observed in DDI2∆ cells? Is it observed in NRF1∆ cells? So we recommend to the authors to decide one of these two options related to Figure 4.*

We decided to remove Figure 4 from this manuscript after performing some experiments related to this figure. We examined bortezomib sensitivity of DDI2 knock-in and knock-out cells as well as Nrf1 knock-out cells. Although DDI2 knock-out cells tended to be more sensitive to bortezomib than DDI2 wild-type knock-in cells, the effect was not significant. Also, at least in our hands, Nrf1 knock-out, which has been shown to increase bortezomib sensitivity, did not confer significant sensitivity to bortezomib in HCT116 cells. As it is known that contribution of Nrf1 on proteasome expression depends on cell types, the results might not be generalized. We also examined whether a synergistic effect of bortezomib and LPV or NFV was observed in DDI2 knock-out or Nrf1 knock-out cells. The synergistic effect was slightly decreased but still observed in both cell lines. Thus, the HIV protease inhibitor could inhibit Nrf1 processing via DDI2 as suggested in our previous Figure 4B. However, since the decrease in the synergistic effect was so modest that we cannot conclude that synergistic cytotoxicity in combination treatment with bortezomib is mainly caused by Nrf1 or DDI2. Accordingly, we deleted sentences regarding Figure 4 in the revised manuscript.

*3) The authors have established DDI2 knock-out cells (DDI2 KO) and DDI2 KO cells in which the WT or protease-dead mutant DDI2 cDNA was knock-in to the DDI2 locus. It would be useful to analyse the processing of Nrf1 in these cell lines upon proteasome inhibition to complement the siRNA knocked down experiments.*

We examined Nrf1 processing in DDI2 knockout, DDI2 WT knock-in, and DDI2 D252N knock-in cells, and the result is newly inserted in [Figure 3C](#fig3){ref-type="fig"}. Defect of Nrf1 cleavage is observed in DDI2 knockout cells and DDI2 D252N knock-in cells as in [Figure 3B](#fig3){ref-type="fig"}, in which the cells were treated with DDI2 siRNA and transfected with D252N cDNA. This results support the idea that DDI2 is a processing enzyme of Nrf1.

*4) The authors should discuss why both forms (FL and P) of Nrf1 are decreasing after co-treatment with bortezomib and lopinavir. Could it be due to cell death or off-target effect of this drug? Is lopinavir treatment alone also decreasing the levels of Nrf1?*

The decrease of Nrf1 after co-treatment with bortezomib and lopinavir is reproducible, but the reason is not clear. Cell death contributed to this result to some extent because co-treatment with bortezomib and 10 μM lopinavir caused cell death. However, Nrf1 was also decreased in combination treatment with bortezomib and 1 μM lopinavir, though cell death was not induced in this condition. This effect was not observed in co-treatment with bortezomib and nelfinavir, suggesting that this was an off-target effect of lopinavir. It is possible that lopiavir itself could decrease the amount of Nrf1. However, it was not confirmed because Nrf1 was hardly detected without proteasome inhibitor. As we decided to delete Figure 4, we did not include discussion regarding this point.
